To the full analysis
Medpace Holdings stock: growth
MEDPMedpace Holdings reported $2.53B in revenue for fiscal 2025, up 20% on the prior year, up 22.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
20.4%
per year from 2013 to 2025, per share 23.3%
Earnings (Annual rate)
27.3%
per year from 2013 to 2025, per share 22.8%
Free cash flow (Annual rate)
18%
per year from 2013 to 2025, per share 20.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 22.3% | 21.6% | 20.4% |
| Revenue per share | 27.5% | 25.5% | 23.3% |
| Earnings | 25.4% | no data | 27.3% |
| Earnings per share | 30.9% | no data | 22.8% |
| Free cash flow | 24.6% | 24.0% | 18.0% |
| Free cash flow per share | 29.9% | 28.0% | 20.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $272.89M | $24.84M | $93.58M |
| 2014 | $290.04M | −$15.57M | $69.89M |
| 2015 | $359.06M | −$8.67M | $79.41M |
| 2016 | $421.58M | $13.43M | $78.2M |
| 2017 | $436.15M | $39.12M | $85.09M |
| 2018 | $704.59M | $73.19M | $140.56M |
| 2019 | $860.97M | $100.44M | $183.96M |
| 2020 | $925.93M | $145.38M | $227.34M |
| 2021 | $1.14B | $181.85M | $235.06M |
| 2022 | $1.46B | $245.37M | $351.17M |
| 2023 | $1.89B | $282.81M | $396.73M |
| 2024 | $2.11B | $404.39M | $572.27M |
| 2025 | $2.53B | $451.12M | $681.87M |
Revenue by segment
How Medpace Holdings, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Oncology30%
- Metabolic29%
- Central Nervous System10%
- Cardiology9%
- Antiviral And Anti Infective5%
- Other16%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Oncology | $651.24M | $747.59M | 29.5% |
| Metabolic | $457.54M | $744.96M | 29.4% |
| Central Nervous System | $181.98M | $254.84M | 10.1% |
| Cardiology | $230.45M | $239.37M | 9.5% |
| Antiviral And Anti Infective | $156.46M | $134.94M | 5.3% |
| Other | $431.38M | $408.55M | 16.1% |
| Total revenue | $2.11B | $2.53B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.